Quanterix Stock News

Wall Street brokerages predict that Quanterix Co. (NASDAQ:QTRX) will post sales of $27.40 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Quanterixs earnings, with the lowest sales estimate coming in at $26.10 million and the highest estimate coming in at $28.85 million. Quanterix reported sales of $26.13 []

Brokerages predict that Quanterix Co. (NASDAQ:QTRX) will announce earnings per share (EPS) of ($0.69) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Quanterixs earnings. The lowest EPS estimate is ($0.71) and the highest is ($0.67). Quanterix posted earnings of ($0.31) per share in the same quarter last []

Quanterix Co. (NASDAQ:QTRX)s share price was up 7.3% during mid-day trading on Friday . The company traded as high as $43.21 and last traded at $43.00. Approximately 6,894 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 334,911 shares. The stock had previously closed at $40.06. Separately, Zacks []

Quanterix (NASDAQ:QTRX) and Cytek BioSciences (NASDAQ:CTKB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends. Institutional and Insider Ownership 82.1% of Quanterix shares are held by institutional investors. Comparatively, 7.3% of Cytek []

Cytek BioSciences (NASDAQ:CTKB) and Quanterix (NASDAQ:QTRX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends. Analyst Recommendations This is a summary of current ratings and price targets for Cytek BioSciences and Quanterix, []

HAMPTON, N.H. , Dec. 9, 2021 /PRNewswire/ -- Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry, announced today that is has raised $300M in capital for its second fund Novalis LifeSciences Investments II, LP. In addition, Paul M. Meister has joined the firm as partner. Novalis LifeSciences is focused on highly innovative Life Science companies. On the occasion of closing the second fund, Marijn E. Dekkers, founder and chairman, said: "This second fund will continue with the investment strategy of Fund I. It will invest in 10-15 companies that are commercializing breakthrough technologies in various segments of the Life Science industry." These segments include biopharma therapeutics, life science tools, genomics, synthetic biology, molecular diagnostics, and agricultural biotechnology all areas with huge unmet needs and exciting opportunities for investors. Some key portfolio companies of Fund I are Ginkgo Bioworks, Cerevel Therapeutics, Decipher Biosciences, Quanterix, and Biotalys, all of which recently became public companies or were acquired.

Quanterix Co. (NASDAQ:QTRX) shares reached a new 52-week low on Monday following insider selling activity. The stock traded as low as $35.02 and last traded at $38.64, with a volume of 227545 shares traded. The stock had previously closed at $37.54. Specifically, VP Dawn Mattoon sold 8,535 shares of the companys stock in a transaction [] The post Quanterix (NASDAQ:QTRX) Sets New 1-Year Low Following Insider Selling appeared first on ETF Daily News .

Quanterix Co. (NASDAQ:QTRX) General Counsel John J. Fry sold 350 shares of the businesss stock in a transaction that occurred on Wednesday, December 1st. The stock was sold at an average price of $40.29, for a total value of $14,101.50. The sale was disclosed in a filing with the SEC, which is available through this []

Quanterix Co. (NASDAQ:QTRX) CEO E Kevin Hrusovsky sold 3,710 shares of the firms stock in a transaction dated Wednesday, December 1st. The stock was sold at an average price of $40.29, for a total value of $149,475.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through []

Quanterix (NASDAQ:QTRX) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation. Profitability This table compares Quanterix and Nautilus Biotechnologys net margins, return on equity and return on []

Wall Street brokerages expect Quanterix Co. (NASDAQ:QTRX) to announce sales of $27.17 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Quanterixs earnings. The highest sales estimate is $28.18 million and the lowest is $26.10 million. Quanterix posted sales of $26.13 million in the same quarter last year, which []

During the last session, Quanterix Corporation (NASDAQ:QTRX)s traded shares were 0.41 million, with the beta value of the company hitting 1.44. At the end of the trading day, the stocks price was $43.96, reflecting an intraday gain of 0.80% or $0.35. The 52-week high for the QTRX share is $92.57, that puts it down -110.58 Given A -110.58% Drop From High, Can Quanterix Corporation (NASDAQ: QTRX) Quickly Recover? Read More »

Global Neurological Biomarkers Market Synopsis: By employing an exceptional Neurological Biomarkers Market report, businesses can get details about market drivers and market restraints which help them to take presumption about reducing or growing the production of particular product. When globalization is

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has been recognized on the Deloitte Technology Fast 500, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. This marks the fourth consecutive year Quanterix has been named to the Technology Fast 500. Being recogn

Quanterix Co. (NASDAQ:QTRX)s stock price fell 7.6% during mid-day trading on Wednesday . The stock traded as low as $49.40 and last traded at $49.65. 4,019 shares were traded during trading, a decline of 99% from the average session volume of 337,831 shares. The stock had previously closed at $53.76. Several brokerages recently issued reports []